Mineralys Therapeutics(MLYS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, PA – Nove ...